Stockreport

Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update

Longeveron Inc. - common stock  (LGVN) 
PDF On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjun [Read more]